ArticlePloS one2021
Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
Ryo Mukai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this papercites it